21 results about "Recombinant peptide" patented technology

The invention relates to isolated synthetic or recombinant peptides comprising an epitope of human tau 2N4R, wherein the tau peptide sequence comprising the epitope is not phosphorylated. The invention also relates to use of such peptides to generate binding molecules, such as antibodies, specific for the non-phosphorylated tau epitopes and to such peptides and binding molecules, such as antibodies, for use in investigation, diagnosis and treatment of tauopathies, such as Alzheimer's disease.

The present invention provides immunogenic compositions comprising a secreted fusion protein, wherein the secreted fusion protein comprises a soluble influenza or rabies virus antigen linked by in-frame fusion to a collagen C-terminal portion capable of self-trimerization to form a disulfide-linked trimeric fusion protein. The present invention also provides uses of the immunogenic compositions for generating an immune response against influenza or rabies infection and for use in vaccine compositions. The present invention also provides methods of producing recombinant peptides and proteins, methods of prevention, treatment, and / or diagnosis, and related kits.

The present invention provides vaccine compositions, methods and uses thereof, the vaccine compositions are immunogenic compositions of secreted fusion proteins, wherein the secreted fusion proteins comprise a rabies or soluble influenza virus antigen linked by in-frame fusion to a collagen C-terminal portion capable of self-trimerization to form a disulfide-linked trimeric fusion protein. The present invention also provides uses of the immunogenic compositions for generating an immune response against rabies or influenza infection and for use in vaccine compositions. The present invention also provides methods of producing recombinant peptides and proteins, methods of prevention, treatment and / or diagnosis and related kits.

The present invention provides a group of compounds for the sequestration of Adeno-associated virus (AAV) and adenovirus (AdV) neutralizing antibodies (NAbs) in a patient. The compounds comprise an inert backbone conjugated with at least one recombinant peptide comprising an epitope. The epitope is a conserved epitope that is targeted by human anti-AAV or anti-AdV NAbs. The backbone where the conserved epitope is conjugated to is a poly-lysine (PLys) or poly-acrylamide (PAA) backbone, among others. Also provided is a pharmaceutical composition comprising this type of compounds, as well as a method for use to treat an individual to inhibit the immune reaction against an AAV or AdV-based therapy. It is also possible to use synthetic compounds for an in vitro detection of anti-AAV or anti-AdV NAbs in a sample.

An immunogenic composition comprising recombinant peptides and proteins comprising respiratory syncytial virus (RSV) viral antigens and immunogens, such as RSVF protein peptides. The immunogenic composition comprises a secreted fusion protein, the secreted fusion protein comprises a soluble RSV virus antigen, and the soluble RSV virus antigen and a collagen C-terminal part are linked through in-frame fusion to form a disulfide bond linked trimeric fusion protein. The immunogenic compositions may be used to generate an immune response, for example, in the treatment or prevention of RSV infection. The immunogenic compositions may be used in vaccine compositions, for example as part of prophylactic and / or therapeutic vaccines. Also provided are methods of producing the recombinant peptides and proteins, prophylactic, therapeutic and / or diagnostic methods, and related kits.

The present invention relates to a vaccine composition for preventing malaria, comprising, as an active ingredient, an elongation factor-2 (EF-2) recombinant protein derived from Plasmodium falciparum and, more specifically, to a vaccine composition for preventing malaria, comprising, as an active ingredient, EF-2 recombinant peptides derived from Plasmodium falciparum consisting of the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2, respectively, and use thereof.

Relates to the field of molecular biology, in particular to polypeptide and application thereof, and a composition for relieving or treating ultraviolet damage, oxidation, inflammation and aging and application thereof.

Disclosed are peptides that are useful as agonists of GPR56. Also disclosed are compositions comprising at least two synthetic or recombinant peptides, each of the peptides comprising a sequence selected from LLSSR, GYYCG, and NQGCKL, or a sequence that has a sequence identity of at least 60% thereto, wherein when a peptide comprises sequence a) or b) the peptide has a length of from 5-25 amino acids and wherein when a peptide comprises sequence c) the peptide has a length of from 6-26 amino acids. The compositions are useful for treating diseases or conditions such as vascular dysfunction, cardiovascular disease, impaired pancreatic -cell function, type II diabetes, impaired glucose tolerance, liver dysfunction, cirrhosis, liver cancer, depression, Alzheimer's disease, retinopathy and Attention deficit hyperactivity disorder.

The object of the invention is a recombinant protein with antibacterial properties having an amino acid sequence derived from the sequence of the M23 domain from Streptococcus thermophilus of a peptidoglycan hydrolase character, preferably in the form of a recombinant protein chimera, as well as compositions comprising it, their uses and methods utilizing thereof. The invention is based on recombinant proteins being peptidoglycan hydrolases with peptidase properties - derived from the M23 domain originating from Streptococcus thermophilus, showing a particularly high specificity to Gram (+) bacteria with a direct cross-linking bridges in peptidoglycan, and discloses the proteins of a recombinant protein chimera such as LB24, additionally comprising a bacteria cell wall binding CWT domain from Staphylococcus pettenkoferi.

The invention relates to isolated recombinant peptides comprising an epitope from human tau 2N4R. The invention also relates to use of such peptides to generate binding molecules, such as antibodies, specific for the tau epitope and to such peptides and antibodies for use in investigation, diagnosis and treatment of tauopathies, such as Alzheimer's disease.

The application discloses a kind of peptidoglycan recognition protein-D, preparation method and application, belong to biological medicine technical field.The application obtains natural peptidoglycan recognition protein-D from tussah by protein separation and purification technology, realizes the expression of peptidoglycan recognition protein-D and its derivative or analogue or partial fragment gene in host cell after resolving its primary structure (gene and protein) using genetic engineering technology, and the antibody of purified recombinant peptidoglycan recognition protein-D and its derivative or analogue or partial fragment is obtained by immunizing animal.The natural, recombinant peptidoglycan recognition protein-D and its derivative or analogue or partial fragment and its antibody of the application can be widely used for prevention, detection diagnosis, treatment and other biological medicine fields of microorganism, microorganism related molecular pattern.

More particularly, the present invention relates to immunogenic compositions comprising recombinant peptides and proteins comprising coronavirus antigens and immunogens, such as SARS-CoV-2 coronavirus Hu-1, its variant Aumitron (BA.5 and / or XBB.1. 5) variants, and / or chimeric antigens and immunogens of other variant S protein peptides or fragments thereof, variant or mutant sequences, for example, SARS-CoV-2 coronavirus Hu-1, its variant Aumitron (BA.5 and / or XBB.1. 5) variants, and / or other variant S protein peptides or fragments thereof. The immunogenic composition comprises a secretory fusion protein comprising a soluble coronavirus antigen, the soluble coronavirus antigen protein being linked by in-frame fusion to a C-terminal portion of collagen capable of self-trimerization to form a disulphide linked trimeric fusion protein. The immunogenic compositions can be used to generate immune responses, and can be used in vaccine compositions. Also provided are methods for producing the recombinant peptides and proteins, prophylactic, therapeutic and / or diagnostic methods, and related kits.

Provided are recombinant polypeptides, pharmaceutical compositions and uses thereof, and methods of preventing or treating cancer. The recombinant polypeptide comprises a first subunit and a second subunit, the first subunit comprises all or fragments of the amino acid sequence of programmed death ligand 1 (PD-L1), and the second subunit comprises all or fragments of the amino acid sequence of a melanoma preferential expression antigen (PRAME). The dual antigen cancer vaccine co-targeting PD-L1 and PRAME effectively prevents, ameliorates or treats cancer and / or inhibits tumor growth in the prophylactic and therapeutic aspects.

This article provides recombinant peptides comprising engineered extracellular domains of viral proteins derived from enveloped viruses. It also provides two-component protein nanostructures and compositions for use in vaccination, generating immune responses, or treating or preventing viral infections.

The present invention relates to methods of producing a conformationally constrained peptide in cellulo using a pnictogen-containing crosslinker. The present invention also relates to conformationally constrained peptides obtainable by said methods and a method for screening peptide libraries for transcription factor agonists that tests whether said conformationally constrained peptide inhibits association between two candidate binding partners. The present invention also relates to the use of a pnictogen-containing cross-linker in a method of producing a conformationally constrained peptide in cellulo. The present invention also relates to recombinant peptides comprising three thiol- / selenol-containing residues linked to a pnictogen-containing cross-linker. The present invention also relates to a kit for use in said methods.

The present invention provides recombinant peptides comprising soluble respiratory syncytial virus (RSV) viral antigens comprising a recombinant F protein peptide joined via an in-frame fusion to a collagen C-terminal portion to form a disulfide-linked trimeric fusion protein, and immunogenic compositions comprising the same. The immunogenic compositions can be used to generate an immune response, e.g., for the treatment or prevention of RSV infection. The immunogenic compositions can be used in vaccine compositions, e.g., as part of a prophylactic and / or therapeutic vaccine.

The present invention discloses immunogenic compositions including recombinant peptides and proteins comprising human immunodeficiency viruses (HIV) antigens and immunogens, e.g., gp 120 protein peptides. In some aspects, the immunogenic composition comprises a secreted fusion protein comprising a soluble HIV viral antigen joined by in-frame fusion to a C-terminal portion of a collagen which is capable of self-trimerization to form a disulfide bond-linked trimeric fusion protein. In some aspects, the immunogenic compositions provided herein are useful for generating an immune response, e.g., for treating or preventing an HIV infection. In some aspects, the immunogenic compositions provided herein may be used in a vaccine composition, e.g., as part of a prophylactic and / or therapeutic vaccine. Also provided herein are methods for producing the recombinant peptides and proteins, prophylactic, therapeutic, and / or diagnostic methods, and related kits.

The invention relates to the technical field of molecular biology and immunity, in particular to urechis unicinctus peptidoglycan recognition protein and a preparation method and application thereof. The amino acid sequence of the urechis unicinctus peptidoglycan recognition protein is as shown in SEQ ID No. 1. The peptidoglycan recognition protein is a recombinant protein obtained by expression in escherichia coli. The recombinant protein can be widely combined and agglutinated with various gram-positive bacteria and gram-negative bacteria, and can promote the removal of pathogenic bacteria in urechis unicinctus. The recombinant peptidoglycan recognition protein can be used for preparing a bacterial agglutination preparation, an anti-bacterial infection preparation and the like, and is especially suitable for prevention and control of aquaculture pathogenic bacteria.

Systems and methods are provided that allow for the determination and prediction of payload toxicity in therapeutic viruses. This document discloses methods for determining the payload toxicity of peptides expressed in cells, comprising: generating or obtaining multiple expression vectors, each containing a different recombinant nucleic acid sequence encoding a corresponding recombinant peptide; expressing the recombinant nucleic acid sequence in multiple host cells while culturing these host cells; sequencing the multiple expression vectors after culturing the host cells; and correlating at least a portion of the recombinant nucleic acid sequence with a toxicity metric.

The present invention relates to a recombinant tamapine peptide of SEQ ID NO: 5 for use as an inhibitor of the migration of cancer cells expressing SK3 channels; wherein the recombinant peptide is characterized in that it comprises the E25K / K27E mutant.